About Matthew Nuñez

Matthew is the Chief Executive Officer of Predictive Health Diagnostics Company.

Predictive Health Diagnostics Company (PDHC) is a leading specialty diagnostics development platform company that develops, manufactures, and distributes medical tests combining science, technology, and proprietary analytics to detect high-risk diseases with significant unmet medical needs. PHDC’s laboratory information systems use data from multiple sources including proteomics, genetics, metabolics, biochemistry, phenotype, and imaging to address among the most challenging clinical problems.

The PULS Cardiac Test measures vascular inflammatory biomarker signals that are secreted directly from the lining of arteries (endothelium) injured by free radicals, infections, or toxins.

The PULS Score integrates this information into a 5-year Acute Coronary Syndrome (ACS-heart attack, unstable angina, or sudden death) risk score that conforms to AHA/ACC guidelines allowing optimal intervention to improve outcomes.

Recommendations for primary prevention of cardiovascular disease have changed. A growing number of guidelines recommend identifying and treating individuals’ overall risk of cardiovascular disease events instead of treating individual risk factors.